Arcellx to present data for Its Phase 1and iMMagine-1studies to treat RRMM

Arcellx (ACLX) announced that it will present clinical data in a poster presentation from its Phase 1 study of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma ; preliminary clinical data in an oral presentation from its iMMagine-1 study in patients with RRMM; and a health-related quality of life systematic literature review and meta-analysis in patients with RRMM in a poster presentation at the 66th American Society of Hematology ASH Annual Meeting and Exposition taking place December 7-10 in San Diego, California. Additionally, an abstract describing the treatment patterns and outcomes in triple-class exposed patients with RRMM will be published in a supplemental issue of Blood in November 2024. The company will also have a medical affairs booth in Hall E of the San Diego Convention Center…Preliminary results from the first 58 patients in the Phase 2 iMMagine-1 study demonstrate deep and durable responses and manageable safety in a high-risk fourth line or higher RRMM population including triple- and penta-class refractory disease. Notably, no delayed neurotoxicities, including no cranial nerve palsies, Guillain-Barre syndrome, or Parkinsonian-like symptoms have been observed with anito-cel to date. Updated Phase 2 data with a more recent data cut will be presented at the oral presentation during ASH.